Repository logo
 

Substitution of Moxifloxacin for Isoniazid during intensive phase treatment of Pulmonary Tuberculosis.

Simple item page
dc.contributor.authorDorman, Susan E.
dc.contributor.authorJohnson, John L.
dc.contributor.authorGoldberg, Stefan.
dc.contributor.authorMuzanye, Grace.
dc.contributor.authorPadayatchi, Nesri.
dc.contributor.authorBozeman, Lorna.
dc.contributor.authorHeilig, Charles M.
dc.contributor.authorBernardo, John.
dc.contributor.authorChoudhri, Shurjeel.
dc.contributor.authorGrosset, Jacques H.
dc.contributor.authorGuy, Elizabeth.
dc.contributor.authorGuyadeen, Priya.
dc.contributor.authorLeus, Maria Corazon.
dc.contributor.authorMaltas, Gina.
dc.contributor.authorMenzies, Dick.
dc.contributor.authorNuermberger, Eric L.
dc.contributor.authorVillarino, Margarita.
dc.contributor.authorVernon, Andrew.
dc.contributor.authorChaisson, Richard E.
dc.date.accessioned2013-07-22T08:38:12Z
dc.date.available2013-07-22T08:38:12Z
dc.date.created2009
dc.date.issued2009
dc.description.abstractRationale: Moxifloxacin has potent activity against Mycobacterium tuberculosis in vitro and in a mouse model of antituberculosis (TB) chemotherapy, but data regarding its activity in humans are limited. Objectives: Our objective was to compare the antimicrobial activity and safety of moxifloxacin versus isoniazid during the first 8 weeks of combination therapy for pulmonary TB. Methods: Adults with sputum smear–positive pulmonary TB were randomly assigned to receive either moxifloxacin 400 mg plus isoniazid placebo, or isoniazid 300 mg plus moxifloxacin placebo, administered 5 days/week for 8 weeks, in addition to rifampin, pyrazinamide, and ethambutol. All doses were directly observed. Sputum was collected for culture every 2 weeks. The primary outcome was negative sputum culture at completion of 8 weeks of treatment. Measurements and Main Results: Of 433 participants enrolled, 328 were eligible for the primary efficacy analysis. Of these, 35 (11%) were HIV positive, 248 (76%) had cavitation on baseline chest radiograph, and 213 (65%) were enrolled at African sites. Negative cultures at Week 8 were observed in 90/164 (54.9%) participants in the isoniazid arm, and 99/164 (60.4%) in the moxifloxacin arm (P=0.37). In multivariate analysis, cavitation and enrollment at an African site were associated with lower likelihood of Week-8 culture negativity. The proportion of participants who discontinued assigned treatment was 31/214 (14.5%) for the moxifloxacin group versus 22/205 (10.7%) for the isoniazid group (RR, 1.35; 95% CI, 0.81, 2.25).Conclusions: Substitution of moxifloxacin for isoniazid resulted in a small but statistically nonsignificant increase in Week-8 culture negativity.en
dc.identifier.citationDorman, S.E., et al. 2009. Substitution of Moxifloxacin for Isoniazid during intensive phase treatment of Pulmonary Tuberculosis. American Journal of Respiratory and Critical Care Medicine 180 (3) pp. 273-280.en
dc.identifier.issn1073-449X
dc.identifier.urihttp://dx.doi.org/10.1164/rccm.200901-0078OCen
dc.identifier.urihttp://hdl.handle.net/10413/9343
dc.language.isoenen
dc.publisherAmerican Thoracic Society.en
dc.subjectTuberculosis, Pulmonary--Drug therapy.en
dc.subjectTuberculosis, Pulmonary--Treatment.en
dc.subjectAntitubercular agents.en
dc.subjectHIV infections--Complications.en
dc.subject.otherMycobacterium infections.en
dc.subject.otherMycobacterium tuberculosis.en
dc.titleSubstitution of Moxifloxacin for Isoniazid during intensive phase treatment of Pulmonary Tuberculosis.en
dc.typePeer reviewed journal articleen

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Dorman_Susan_E_2009.pdf
Size:
236.13 KB
Format:
Adobe Portable Document Format
Description:
Journal article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.64 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Research papers (Caprisa)